search
Back to results

Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Dapagliflozin
Dapagliflozin placebo
Sponsored by
AstraZeneca
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes focused on measuring Diabetes Mellitus, Dapagliflozin, Placebo, Insulin resistance, Metabolic Diseases

Eligibility Criteria

10 Years - 24 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria

  1. Provision of informed consent prior to any study-specific procedures
  2. Males and Females, ages 10 years of age, up to but not including 25 years of age at the time of randomization
  3. Previously diagnosed as having type 2 diabetes for at least 2 months by WHO/ADA diagnostic criteria
  4. HbA1c >= 6.5% and <= 11% obtained at screening visit
  5. Currently on diet and exercise and a stable dose of metformin (at least 1000 mg daily) for a minimum of 8 weeks, or stable dose of insulin for a minimum of 8 weeks, or a stable combination of metformin (at least 1000 mg daily) and insulin for a minimum of 8 weeks prior to screening
  6. FPG <=255 mg/dL (<= 14.2 mmol/L) obtained at screening visit

Exclusion Criteria:

  1. Previous diagnosis of Type 1 diabetes
  2. Diabetes ketoacidosis (DKA) within 6 months of screening
  3. Current use of the following medications for the treatment of diabetes, or use within the specified timeframe prior to screening for the main study:

    • Eight weeks: sulfonylureas, alpha glucosidase inhibitors, metiglinide, or injectable incretins or incretin mimetics or other antidiabetes medications not otherwise specified
    • Sixteen weeks: thiazolidinediones
    • Any previous history or current use of an SGLT2 inhibitor, including dapagliflozin
  4. Initiation or discontinuation of prescription or non-prescription weight loss drugs within 8 weeks of screening.

    Use of prescription or non-prescription weight loss drugs must be stable during the study

  5. Pregnant, positive serum pregnancy test, planning to become pregnant during the clinical trials, or breastfeeding
  6. History of unstable or rapidly progressive renal disease
  7. History of unresolved vesico-ureteral reflux
  8. Replacement or chronic systemic corticosteroid therapy, defined as any dose of systemic corticosteroid taken for > 4 weeks within 3 months prior to the Day 1 visit.

    Note: Topical, nasal, or inhaled corticosteroids are allowed

  9. Abnormal renal function, which is defined in subjects < 18 years of age as an estimated glomerular filtration rate (eGFR) calculated by the Schwartz Formula < 80 mL/min/1.73 m2 (1.33 mL/s), and in subjects >= 18 years as an estimated glomerular filtration rate (eGFR) calculated by the MDRD Formula < 60 mL/min/1.73 m2 (1.33 mL/s)
  10. Presence of either: antibodies to glutamic acid decarboxylase (GAD) or protein tyrosine phosphatase-like protein antibodies (IA-2)
  11. An abnormal TSH value at screening will be further evaluated for free T4. Subjects with abnormal free T4 values will be excluded
  12. Hematuria (confirmed by microscopy at screening) with no explanation as judged by the investigator up to randomization
  13. Anemia of any etiology defined as hemoglobin <=10.7 g/dL (107 g/L) for females and <= 11.3 g/dL (113 g/L) for males. Subjects who are considered to have anemia according to local guidelines should be excluded
  14. Volume-depleted subjects. Subjects at risk for volume depletion due to co-existing conditions or concomitant medications, such as loop diuretics, should carefully monitor their volume status

Sites / Locations

  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Dapagliflozin

Dapagliflozin placebo

Arm Description

Outcomes

Primary Outcome Measures

Adjusted Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 24

Secondary Outcome Measures

Adjusted Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
Percentage of Participants Who Required Glycemic Rescue Medication or Permanently Discontinued Treatment Due to Lack of Glycemic Control
Percentage of Participants With Baseline Glycated Haemoglobin (HbA1c) >= 7% Who Achieved HbA1c Level < 7% at Week 24

Full Information

First Posted
March 29, 2016
Last Updated
January 28, 2022
Sponsor
AstraZeneca
Collaborators
Parexel, Q2 Solutions, PRA Health Sciences, Covance Laboratories, Inc
search

1. Study Identification

Unique Protocol Identification Number
NCT02725593
Brief Title
Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years
Official Title
A 24 Week, Multicenter, Randomized, Double-Blind, Parallel Group, Phase 3 Trial With a 28 Week Long Term Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 10 mg in T2DM Patients Aged 10-24 Years
Study Type
Interventional

2. Study Status

Record Verification Date
January 2022
Overall Recruitment Status
Completed
Study Start Date
June 22, 2016 (Actual)
Primary Completion Date
April 6, 2020 (Actual)
Study Completion Date
April 6, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca
Collaborators
Parexel, Q2 Solutions, PRA Health Sciences, Covance Laboratories, Inc

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A trial of patients aged 10-24 years with type 2 diabetes mellitus to evaluate the comparative efficacy and safety between dapagliflozin and Placebo.
Detailed Description
A 24 Week, Multicenter, Randomized, Double-Blind, Parallel Group, Phase 3 Trial with a 28 Week Long Term Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 10 mg in T2DM Patients aged 10-24 years

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Diabetes Mellitus, Dapagliflozin, Placebo, Insulin resistance, Metabolic Diseases

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
72 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Dapagliflozin
Arm Type
Experimental
Arm Title
Dapagliflozin placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Dapagliflozin
Other Intervention Name(s)
FORXIGA
Intervention Description
Dapagliflozin 10 mg tablets administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily, for the 28-week site and subject blinded long term extension.
Intervention Type
Drug
Intervention Name(s)
Dapagliflozin placebo
Intervention Description
matching placebo tablets, administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily,for the 28-week site and subject blinded long term extension.
Primary Outcome Measure Information:
Title
Adjusted Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 24
Time Frame
Baseline to Week 24
Secondary Outcome Measure Information:
Title
Adjusted Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
Time Frame
Baseline to Week 24
Title
Percentage of Participants Who Required Glycemic Rescue Medication or Permanently Discontinued Treatment Due to Lack of Glycemic Control
Time Frame
Baseline to Week 24
Title
Percentage of Participants With Baseline Glycated Haemoglobin (HbA1c) >= 7% Who Achieved HbA1c Level < 7% at Week 24
Time Frame
Baseline to Week 24

10. Eligibility

Sex
All
Minimum Age & Unit of Time
10 Years
Maximum Age & Unit of Time
24 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria Provision of informed consent prior to any study-specific procedures Males and Females, ages 10 years of age, up to but not including 25 years of age at the time of randomization Previously diagnosed as having type 2 diabetes for at least 2 months by WHO/ADA diagnostic criteria HbA1c >= 6.5% and <= 11% obtained at screening visit Currently on diet and exercise and a stable dose of metformin (at least 1000 mg daily) for a minimum of 8 weeks, or stable dose of insulin for a minimum of 8 weeks, or a stable combination of metformin (at least 1000 mg daily) and insulin for a minimum of 8 weeks prior to screening FPG <=255 mg/dL (<= 14.2 mmol/L) obtained at screening visit Exclusion Criteria: Previous diagnosis of Type 1 diabetes Diabetes ketoacidosis (DKA) within 6 months of screening Current use of the following medications for the treatment of diabetes, or use within the specified timeframe prior to screening for the main study: Eight weeks: sulfonylureas, alpha glucosidase inhibitors, metiglinide, or injectable incretins or incretin mimetics or other antidiabetes medications not otherwise specified Sixteen weeks: thiazolidinediones Any previous history or current use of an SGLT2 inhibitor, including dapagliflozin Initiation or discontinuation of prescription or non-prescription weight loss drugs within 8 weeks of screening. Use of prescription or non-prescription weight loss drugs must be stable during the study Pregnant, positive serum pregnancy test, planning to become pregnant during the clinical trials, or breastfeeding History of unstable or rapidly progressive renal disease History of unresolved vesico-ureteral reflux Replacement or chronic systemic corticosteroid therapy, defined as any dose of systemic corticosteroid taken for > 4 weeks within 3 months prior to the Day 1 visit. Note: Topical, nasal, or inhaled corticosteroids are allowed Abnormal renal function, which is defined in subjects < 18 years of age as an estimated glomerular filtration rate (eGFR) calculated by the Schwartz Formula < 80 mL/min/1.73 m2 (1.33 mL/s), and in subjects >= 18 years as an estimated glomerular filtration rate (eGFR) calculated by the MDRD Formula < 60 mL/min/1.73 m2 (1.33 mL/s) Presence of either: antibodies to glutamic acid decarboxylase (GAD) or protein tyrosine phosphatase-like protein antibodies (IA-2) An abnormal TSH value at screening will be further evaluated for free T4. Subjects with abnormal free T4 values will be excluded Hematuria (confirmed by microscopy at screening) with no explanation as judged by the investigator up to randomization Anemia of any etiology defined as hemoglobin <=10.7 g/dL (107 g/L) for females and <= 11.3 g/dL (113 g/L) for males. Subjects who are considered to have anemia according to local guidelines should be excluded Volume-depleted subjects. Subjects at risk for volume depletion due to co-existing conditions or concomitant medications, such as loop diuretics, should carefully monitor their volume status
Facility Information:
Facility Name
Research Site
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06514-3434
Country
United States
Facility Name
Research Site
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20010
Country
United States
Facility Name
Research Site
City
Gainesville
State/Province
Florida
ZIP/Postal Code
32610
Country
United States
Facility Name
Research Site
City
Homestead
State/Province
Florida
ZIP/Postal Code
33032
Country
United States
Facility Name
Research Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33015
Country
United States
Facility Name
Research Site
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Facility Name
Research Site
City
Bronx
State/Province
New York
ZIP/Postal Code
10467
Country
United States
Facility Name
Research Site
City
Buffalo
State/Province
New York
ZIP/Postal Code
14222
Country
United States
Facility Name
Research Site
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43205
Country
United States
Facility Name
Research Site
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
Research Site
City
Greenville
State/Province
South Carolina
ZIP/Postal Code
29615
Country
United States
Facility Name
Research Site
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38116
Country
United States
Facility Name
Research Site
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38119
Country
United States
Facility Name
Research Site
City
Lampasas
State/Province
Texas
ZIP/Postal Code
76550
Country
United States
Facility Name
Research Site
City
McAllen
State/Province
Texas
ZIP/Postal Code
78503
Country
United States
Facility Name
Research Site
City
Budapest
ZIP/Postal Code
1023
Country
Hungary
Facility Name
Research Site
City
Nyíregyháza
ZIP/Postal Code
4400
Country
Hungary
Facility Name
Research Site
City
Beer Sheva
ZIP/Postal Code
84101
Country
Israel
Facility Name
Research Site
City
Haifa
ZIP/Postal Code
91096
Country
Israel
Facility Name
Research Site
City
Jerusalem
ZIP/Postal Code
91120
Country
Israel
Facility Name
Research Site
City
Ramat Gan
ZIP/Postal Code
5265601
Country
Israel
Facility Name
Research Site
City
Zerifin
ZIP/Postal Code
70300
Country
Israel
Facility Name
Research Site
City
Culiacan
ZIP/Postal Code
80230
Country
Mexico
Facility Name
Research Site
City
Guadalajara
ZIP/Postal Code
44670
Country
Mexico
Facility Name
Research Site
City
Merida
ZIP/Postal Code
97134
Country
Mexico
Facility Name
Research Site
City
Monterrey
ZIP/Postal Code
64460
Country
Mexico
Facility Name
Research Site
City
México, D.F.
ZIP/Postal Code
11410
Country
Mexico
Facility Name
Research Site
City
Zapopan
ZIP/Postal Code
45116
Country
Mexico
Facility Name
Research Site
City
Oradea
ZIP/Postal Code
410169
Country
Romania
Facility Name
Research Site
City
Timisoara
ZIP/Postal Code
300011
Country
Romania
Facility Name
Research Site
City
Izhevsk
ZIP/Postal Code
426009
Country
Russian Federation
Facility Name
Research Site
City
Krasnoyarsk
ZIP/Postal Code
660022
Country
Russian Federation
Facility Name
Research Site
City
Moscow
ZIP/Postal Code
117036
Country
Russian Federation
Facility Name
Research Site
City
Novosibirsk
ZIP/Postal Code
630087
Country
Russian Federation
Facility Name
Research Site
City
Pyatigorsk
ZIP/Postal Code
357500
Country
Russian Federation
Facility Name
Research Site
City
Rostov-on-Don
ZIP/Postal Code
344022
Country
Russian Federation
Facility Name
Research Site
City
Samara
ZIP/Postal Code
443079
Country
Russian Federation
Facility Name
Research Site
City
Saratov
ZIP/Postal Code
410054
Country
Russian Federation
Facility Name
Research Site
City
St. Petersburg
ZIP/Postal Code
194100
Country
Russian Federation
Facility Name
Research Site
City
Tomsk
ZIP/Postal Code
634050
Country
Russian Federation
Facility Name
Research Site
City
Kent
ZIP/Postal Code
CT9 4AN
Country
United Kingdom
Facility Name
Research Site
City
Leicester
ZIP/Postal Code
LE15WW
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD Sharing Time Frame
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing Access Criteria
When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing URL
https://astrazenecagroup-dt.pharmacm.com/DT/Home
Citations:
PubMed Identifier
35378069
Citation
Tamborlane WV, Laffel LM, Shehadeh N, Isganaitis E, Van Name M, Ratnayake J, Karlsson C, Norjavaara E. Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study. Lancet Diabetes Endocrinol. 2022 May;10(5):341-350. doi: 10.1016/S2213-8587(22)00052-3. Epub 2022 Apr 1.
Results Reference
derived
Links:
URL
https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D1690C00017&amp;attachmentIdentifier=a9e77cda-496a-4e09-aa87-cbe0538b927b&amp;fileName=D1690C00017_CSP_redacted.pdf&amp;versionIdentifier=
Description
D1690C00017_CSP_redacted
URL
https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D1690C00017&amp;attachmentIdentifier=27e64a31-b91e-45ea-bd34-12f4c16b9806&amp;fileName=D1690C00017_SAP_redacted.pdf&amp;versionIdentifier=
Description
D1690C00017_SAP_redacted

Learn more about this trial

Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years

We'll reach out to this number within 24 hrs